2022
DOI: 10.1016/j.heliyon.2022.e12373
|View full text |Cite
|
Sign up to set email alerts
|

Severe hypertrophic cardiomyopathy in a patient with a homozygous MYH7 gene variant

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 17 publications
(12 reference statements)
0
2
0
Order By: Relevance
“…To explore the potential role of HSPD1 in HNSCC, we systematically examined differentially expressed genes (DEGs) categorized by HSPD1 expression levels. Among the upregulated DEGs, MYH7 is associated with hypertrophic obstructive cardiomyopathy, and mutations in the MYH7 gene are linked to various myocardial diseases [33] . PAK5 is implicated in the development of multiple tumors; it enhances n-calmodulin trans-activation to promote metastasis in renal cell carcinoma [34] and contributes to cervical cancer progression through modi cations [35] .…”
Section: Knockdown Of Hspd1 Inhibits Hnscc Cell Growth In Vitromentioning
confidence: 99%
“…To explore the potential role of HSPD1 in HNSCC, we systematically examined differentially expressed genes (DEGs) categorized by HSPD1 expression levels. Among the upregulated DEGs, MYH7 is associated with hypertrophic obstructive cardiomyopathy, and mutations in the MYH7 gene are linked to various myocardial diseases [33] . PAK5 is implicated in the development of multiple tumors; it enhances n-calmodulin trans-activation to promote metastasis in renal cell carcinoma [34] and contributes to cervical cancer progression through modi cations [35] .…”
Section: Knockdown Of Hspd1 Inhibits Hnscc Cell Growth In Vitromentioning
confidence: 99%
“…Gene dosage also affects prognosis in HCM [ 3 , 138 ]. Among HCM patients who exhibit two (digenic) or several (oligogenic) causal mutations in the same or different genes, the severity of ventricular hypertrophy appears to be more pronounced.…”
Section: Interconnections Of Genetic Basis and Outcomes In Hcmmentioning
confidence: 99%
“…Although surgical treatment is possible, there is no perfect drug-based solution. Among patients with HCM and a pathogenic sarcomeric gene variant, 70% are involved in beta myosin heavy chain 7 (MYH7) and myosin-binding protein C3 (MYBPC3), whereas other genes ( MYL2, TNNI3, TNNT2, MYL3, ACTC1, TPM1 ) each account for a small proportion of patients (1–5%) ( 4 , 5 ). The precise mechanisms of HCM have not been fully analyzed.…”
Section: Introductionmentioning
confidence: 99%